Earnings ·
Pharming posts $117.6M Q3 revenue, raises full-year guidance to $380-$390M
PHARPharming Group N.V.
Pharming Group reported third-quarter total revenues of US$117.6 million, a 21% increase year-over-year that exceeded market expectations. RUCONEST sales rose 14% to US$93.8 million as U.S. demand stabilized, while Joenja revenue surged 58% to US$23.8 million driven by international launches and strong U.S. uptake. Operating profit nearly doubled to US$29.9 million, up 89%, supported by higher sales and favorable foreign exchange movements. The company tightened its full-year revenue guidance to a range of US$380 million to US$390 million. Additionally, Pharming announced positive Phase II data for leniolisib in genetically identifiable primary immunodeficiencies and expects further CVID trial results in November 2026. Pharming Group N.V. is a global biotechnology company that develops and commercializes innovative medicines for people living with rare immune and genetic diseases.